The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Brawn Biotech Ltd

Brawn Biotech Ltd

BSE 530207 · NSE BRAWN · ISIN INE899B01015 · Group X · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹23.00

+0.00%

BSE close, 28 August 2026

Market cap

₹6.90 cr

0.3 cr shares · Micro cap

Free float

₹2.30 cr

as published

P/E · P/B

8.0× · 1.63×

EPS ₹2.86 · BV ₹14.11

FY25-26 rev / PAT

16.98 / 0.94

₹ cr, as filed

Filings, window

13

2 selected · 15%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹17.71 52-WK HIGH ₹24.37 ₹23.00 79% of range
Against 52-week high-5.6%
Against 52-week low+29.9%
Day change+0.00%
Size bandMicro cap
Index membershipNone

Valuation as published by BSE

Earnings per share₹2.86
Price / earnings8.04×
Price / book1.63×
Book value — derived, price ÷ P/B₹14.11
Return on equity20.28%
Operating margin3.03%
Net margin2.53%

Consistency check

P/B ÷ P/E, which must equal ROE
20.27%
ROE as published
20.28%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 6.08 0.15 0.52 3.03% 2.53%
Mar-26 · Q 1.98 0.58 1.95 -16.39% 29.49%
FY25-26 16.98 0.94 3.26 0.75% 5.54%

Quarter on quarter

Revenue, quarter on quarter
+207.1%
Net profit, quarter on quarter
-74.1%
Operating margin, quarter on quarter
+1,942 bps

Disclosure profile 13 filings in the window

0 median 17.0 p75 · 25 sector max 52 13 34th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Board Outcome1
Results1
Selected sub-total2
Procedural
AGM / EGM4
General2
Newspaper Publication2
Annual Report1
Board Meeting1
Trading Window1
Procedural sub-total11
Total13

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group X, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

13 filings · 2 selected · busiest 2026-09-29

Filing rhythm · the twelve most recent

2026-08-132026-09-29

SelectedProcedural

Filings

13 in the window · 2 earlier on record

  1. 29 September 2026 ·

    General

    Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Disclosure under Regulation 30 of SEBI LODR Regulations, 2015

    Company Update / General View filing →

  2. 29 September 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Scrutinizers Report attached along with voting results for 41st AGM

    AGM/EGM / AGM View filing →

  3. 29 September 2026 ·

    AGM / EGM

    Proceedings Of 41St AGM

    Proceedings of 41st AGM

    AGM/EGM / AGM View filing →

  4. 29 September 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Outcome of 41st Annual General Meeting

    AGM/EGM / AGM View filing →

  5. 28 September 2026 ·

    Trading Window

    Closure of Trading Window

    Closure of Trading Window for quarter ended 30.09.2026

    Insider Trading / SAST / Closure of Trading Window View filing →

  6. 2 September 2026 ·

    General

    Intimation W.R.T Letter Sent To Shareholders As Per Reg 36

    Letters sent to shareholders as per Reg 36

    Company Update / General View filing →

  7. 2 September 2026 ·

    Newspaper Publication

    Newspaper Publication

    Newspaper Publication for 41st Notice of AGM.

    Company Update / Newspaper Publication View filing →

  8. 1 September 2026 ·

    Annual Report

    Reg. 34 (1) Annual Report.

    ANNUAL REPORT FOR FY 2025-26

    Others / Reg. 34 (1) Annual Report View filing →

  9. 1 September 2026 ·

    AGM / EGM

    Notice Of 41St AGM To Be Held On 29.09.2026

    Notice of 41st AGM to be held on 29.09.2026

    AGM/EGM / AGM View filing →

  10. 14 August 2026 ·

    Newspaper Publication

    Newspaper Publication

    Publication of Un-audited financial results for the quarter ended June 30, 2026.

    Company Update / Newspaper Publication View filing →

  11. 13 August 2026 ·

    Results

    Outcome Of Board Meeting Held On August 13, 2026 To Consider And Approve, Inter-Alia, Un-Audited Financial Results Of The Company For Quarter Ended June 30, 2026.

    Outcome of Board Meeting held on August 13, 2026 to consider and approve, inter-alia, un-audited financial results of the company for quarter ended June 30, 2026.

    Result / Financial Results View filing →

  12. 13 August 2026 ·

    Board Outcome

    Board Meeting Outcome for Outcome Of Board Meeting Held On August 13, 2026 To Consider And Approve, Inter-Alia, Un-Audited Financial Results Of The Company For Quarter Ended June 30, 2026.

    Outcome of Board Meeting held on August 13, 2026 to consider and approve, inter-alia, un-audited financial results of the company for quarter ended June 30, 2026.

    Board Meeting / Outcome of Board Meeting View filing →

  13. 5 August 2026 ·

    Board Meeting

    Board Meeting Intimation for Consideration And Approval Of, Inter Alia, The Un-Audited Financial Results Of The Company For The Quarter Ended June 30, 2026.

    Brawn Biotech Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Un-Audited Financial Results ....

    Board Meeting / Board Meeting View filing →

RSS feed for Brawn Biotech Ltd · the 50 most recent filings